HWP
CRNX icon

Highline Wealth Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Highline Wealth Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57
Closed -$1.91K – 937
2025
Q1 		$1.91K Buy
+57
New +$2.13K ﹤0.01% 639

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highline Wealth Partners's CRNX Position: Q2 2025 in Review

Highline Wealth Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 57 shares — an estimated $1.91K sold.

Highline Wealth Partners first reported a position in CRNX in Q1 2025 and held it in 1 quarter. The position peaked at $1.91K in Q1 2025. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Highline Wealth Partners reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Highline Wealth Partners sold 57 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $1.91K.
  • Highline Wealth Partners first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Highline Wealth Partners's Crinetics Pharmaceuticals position peaked at $1.91K in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.